ALS Invest 1 B.V. 4
4 · Amylyx Pharmaceuticals, Inc. · Filed May 5, 2022
Insider Transaction Report
Form 4
ALS Invest 1 B.V.
10% Owner
Transactions
- Conversion
Common Stock
2022-01-11+1,129,386→ 1,129,386 total - Conversion
Common Stock
2022-01-11+4,826,503→ 5,955,889 total - Conversion
Series A Preferred Stock
2022-01-11−1,129,386→ 0 total→ Common Stock (1,129,386 underlying) - Conversion
Series B Preferred Stock
2022-01-11−4,826,503→ 0 total→ Common Stock (4,826,503 underlying)
Footnotes (2)
- [F1]Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.
- [F2]The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person.